Literature DB >> 17510784

Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles.

Lizhong Luo1, Yan Li, Soon Duck Ha, C Yong Kang.   

Abstract

Virus-like particles (VLPs) of numerous viruses have been considered as possible candidates for vaccine development. We have constructed HIV chimeric genes by coupling the gag gene of HIV-2 with the V3 domain of the gp120 gene of either HIV-1 or HIV-2 and expressed the chimeric genes in SF21 cells using the recombinant baculovirus expression system. Although the level of expression of the chimeric HIV-2 gag gene with the V3 domain of either HIV-1 gp120 (gagC-1V3) or HIV-2 gp120 (gagC-2V3) was high, the VLP assembly and extracellular release of GagC-1V3 was very poor. In contrast, GagC-2V3 chimeric proteins formed VLPs and released efficiently. We have constructed substitution mutants to investigate the effects of the hydrophobic region of the V3 domain of HIV-1 Gp120 (1V3) in VLP assembly and release. The substitution mutant analyses revealed that in replacing the hydrophobic region of the 1V3 in GagC-1V3 with the hydrophilic sequence of the V3 domain of HIV-2 Gp120 (2V3) enhanced the extracellular VLP. We demonstrate here that disruption of the hydrophobic character of the C-terminus of the chimeric protein improves assembly and release of the VLPs. Our results suggest that the poor GagC-1V3 VLP release was attributed to the hydrophobic region in the V3 sequence of the chimeric protein, and that not only the N-terminal myristylation and positively charged domain of the Gag protein functioned as a targeting signal to direct membrane binding, but also that the C-terminal hydrophobic region affected release of chimeric VLPs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510784     DOI: 10.1007/s11262-007-0108-x

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  32 in total

1.  Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes.

Authors:  Masahiro Niikura; Shiki Takamura; Gisen Kim; Satoru Kawai; Masayuki Saijo; Shigeru Morikawa; Ichiro Kurane; Tian-Cheng Li; Naokazu Takeda; Yasuhiro Yasutomi
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

2.  Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.

Authors:  C Y Kang; L Luo; M A Wainberg; Y Li
Journal:  Biol Chem       Date:  1999-03       Impact factor: 3.915

3.  Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells.

Authors:  L Luo; Y Li; C Y Kang
Journal:  Virology       Date:  1990-12       Impact factor: 3.616

4.  Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

Authors:  C Sedlik; M Saron; J Sarraseca; I Casal; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

5.  Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection.

Authors:  S Laurent; J F Vautherot; M F Madelaine; G Le Gall; D Rasschaert
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice.

Authors:  J M Ball; M E Hardy; R L Atmar; M E Conner; M K Estes
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine.

Authors:  Asato Kojima; Atsushi Yasuda; Hideki Asanuma; Toyokazu Ishikawa; Akihisa Takamizawa; Kotaro Yasui; Takeshi Kurata
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.

Authors:  P Roy; D H Bishop; H LeBlois; B J Erasmus
Journal:  Vaccine       Date:  1994-07       Impact factor: 3.641

9.  Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.

Authors:  Yuxian He; William J Honnen; Chavdar P Krachmarov; Michael Burkhart; Samuel C Kayman; Jose Corvalan; Abraham Pinter
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

10.  Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection.

Authors:  R Wagner; V J Teeuwsen; L Deml; F Notka; A G Haaksma; S S Jhagjhoorsingh; H Niphuis; H Wolf; J L Heeney
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.